Trial Profile
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Alvocidib (Primary) ; Cytarabine; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms Zella 201
- Sponsors Sumitomo Pharma Oncology; Tolero Pharmaceuticals
- 08 Dec 2020 Results (n=13) of newly diagnosed high-risk exploratory arm, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 05 Dec 2020 Results presented in a Sumitomo Dainippon Pharma media release.
- 05 Dec 2020 According Sumitomo Dainippon Pharma media release, data from this trial were presented at 62nd American Society of Hematology Annual Meeting